Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
Condition: HER2-positive Breast Cancer Intervention: Drug: trastuzumab deruxtecan (T-DXd) (IV) Sponsor: Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Ireland Health | Neoadjuvant Therapy | Research | Study